Non-small cell lung cancer (NSCLC)

Rivera, DR, Lasiter, L, Christian, JB, Enewold, L, Espirito, JL, Hansen, E, Henk, HJ, Kushi, L, Lane, D, Natanzon, Y, Benito, RP, Rasmussen, E, Robert, NJ, Stewart, M, Sweetnam, C, Tymejczyk, O, Valice, E, Wagner, J, Zander, A, Allen, J

May 2020

Abstract

ASCO Annual Meeting

Flatiron-authored

STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort →

Papillon-Cavanagh, S, Doshi, P, Dobrin, R, Szustakowski, J, Walsh, AM

April 2020

Manuscript

ESMO Open

Real-world outcomes for advanced non-small cell lung cancer patients treated with a PD-(L)1 inhibitor beyond progression →

Stinchcombe, TE, Miksad, RA, Gossai, A, Griffith, SD, Torres, AZ

April 2020

Manuscript

Clinical Lung Cancer

Flatiron-authored

Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer →

Sheinson, D, Wong, WB, Wu, N, Mansfield, AS

April 2020

Manuscript

Lung Cancer

Prognostic significance of cancer patient reported outcomes in cancer →

Kerrigan, KC, Patel, SB, Halland, B, Ose, D, Chalmers, AW, Haydell, T, Meropol, NJ, Akerley, WL

January 2020

Manuscript

Journal of Oncology Practice

Flatiron-authored

Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice

Drakaki, A, Dhillon, PK, Wakelee, H, Chui, S, Shim, J, Kent, M, Degaonkar, V, Hoang, T, McNally, V, Luhn, P, Gutzmer, R

December 2019

Abstract

ESMO Immuno-Oncology Congress

Brain metastases, treatment patterns, and outcomes in ROS1-positive NSCLC patients from US oncology community centers →

Krebs M,G, Perez, L, Surinach, A, Doebele, RC, Martina, R, Martinec, M, Riehl, T, Meropol, NJ, Wong, WB, Crane, G

November 2019

Abstract

ESMO Asia

Flatiron-authored

Cancer immunotherapy use and effectiveness in real-world patients living with HIV →

Adamson, BJS, Cohen, AB, Cheever, MA, Hooley, IJ, Williams, ER, Tymejczyk, O, Peeples, M, Hernandez, M, Meropol, NJ, Uldrick, TS

October 2019

Abstract

International Conference on Malignancies in HIV/AIDS

Flatiron-authored

Real-world outcomes associated with the use of companion diagnostics in NSCLC, Flatiron Health 2011-2018 →

John, A.

October 2019

Abstract

Asian Conference on Pharmacoepidemiology

Brain metastases, treatment patterns, and outcomes in ROS1-positive NSCLC patients from US oncology community centers →

Krebs, MG, Perez, L, Surinach, A, Doebele, RC, Martina, R, Martinec, M, Riehl, T, Meropol, NJ, Wong, WB, Crane, G

October 2019

Abstract

ESMO Annual Congress

Flatiron-authored

Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) →

Cohen, AB, Neri, B, Adamson, BJS, Scanlon, CM, Gross, CP, Meropol, NJ, Miksad, RA

October 2019

Abstract

ESMO Annual Congress

Flatiron-authored

Treatment patterns and outcomes for patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer (NSCLC) in US clinical practice →

Krebs, MG, Polito, L, Smoljanovic, V, Trinh, H, Crane, G

September 2019

Abstract

ESMO Annual Congress

Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC) →

Ma, X, Nussbaum, NC, Magee, K, Bourla, AB, Tucker, MG, Bellomo, L, Bennette, CS

September 2019

Abstract

ESMO Annual Congress

Flatiron-authored

Analysis of tumor mutational burden, cancer immunotherapy use, and outcomes based on genomic ancestry in non-small cell lung cancer patients treated in community practice in the United States →

Richie, N, Luhn, P, Ogbu, U, Wilson, GK, Brawley, OW

September 2019

Abstract

AACR Special Meeting

Cost effectiveness of PD-L1-based test-and-treat strategy with pembrolizumab as the first-line treatment for metastatic NSCLC in Hong Kong →

Loong HH, Wong CKH, Leung LKS, Dhankhar P, Insinga RP, Chandwani S, Hsu DC, Lee MYK, Huang M, Pellissier J, Rai A, Achra M, Tan SC

September 2019

Manuscript

Pharmacoeconomics Open

Real-world clinical and economic outcomes and the role of bevacizumab in non-small cell lung cancer patients with liver metastases →

Wong, WB, Wu, N, Yang, E, Davies, J, Chae, YK

September 2019

Manuscript

Journal of Oncology Practice

LKB1 mutations in metastatic non-small cell lung cancer (mNSCLC): Prognostic value in the real world →

Golozar, A, Collins, J, Fraeman, K, Nordstrom, BL, McEwen, R, Shire, N, Higgs, B

September 2019

Abstract

World Conference on Lung Cancer

Real-world treatment patterns and survival in non-small cell lung cancer patients with EGFR exon 20 insertion mutations →

Dersarkissian, M, Bhak, R, Lin, HM, Li, S, Cheng, M, Lax, A, Huang, H, Duh, MS, Ou, S-H

September 2019

Abstract

World Conference on Lung Cancer

Real-world treatment patterns and outcomes in ALK+ NSCLC patients receiving immuno-oncology therapy in the United States →

Pan, X, Lin, HM, Yin, Y, Cheng, M-R, Baumann, P, Jahanzeb, M

September 2019

Abstract

World Conference on Lung Cancer

Pembrolizumab for previously treated PD-L1-expressing advanced NSCLC: Real-world time on treatment and overall survival →

Velcheti, V, Chandwani, S, Chen, X, Piperdi, B, Burke, T

September 2019

Abstract

World Conference on Lung Cancer

Real-world trends in systemic therapy for nonsquamous EGFR/ALK-negative advanced NSCLC (aNSCLC) in the U.S., 2011-2018 →

Velcheti, V, Chandwani, S, Chen, X, Piperdi, B, Burke, T

September 2019

Abstract

World Conference on Lung Cancer

Temporal trends in treatment patterns for advanced/metastatic non-small cell lung cancer (aNSCLC) in routine clinical practice →

Stefaniak, VJ, Winfree, KB, Molife, C

September 2019

Abstract

World Conference on Lung Cancer

Rates of systemic anticancer therapy (SACT) for advanced non-small cell lung cancer (aNSCLC) in the U.S. 2011-2018. →

Velcheti, V, Chandwani, S, Chen, X, Piperdi, B, Burke, T

September 2019

Abstract

World Conference on Lung Cancer

Lung cancer prognostic index performance in U.S. real-world advanced non-small cell lung cancer patients →

Shah, RA, John, A, Alexander, M

September 2019

Abstract

World Conference on Lung Cancer

Real-world trends in systemic anticancer therapy (SACT) for squamous advanced NSCLC (aNSCLC) in the U.S. 2011-2018 →

Velcheti, V, Chandwani, S, Chen, X, Piperdi, B, Burke, T

September 2019

Abstract

World Conference on Lung Cancer

BRAF mutations are associated with increased benefit from PD-1/PD-L1 blockade compared with other oncogenic drivers in non-small cell lung cancer →

Heymach, JV, Shames, DS, Albacker, LA, Frampton, GM, Alexander, BM, Miller, VA, Glisson, BS, Gibbons, DL, Papadimitrakopoulou, V, Tsao, AS, Lee, J, Swisher, S, Roth, JA, Simon, GS, Rinsurongkawong, W, Barreto, D, Zhang, J, Wu, C-J, Goldberg, ME, Le, X, Elamin, Y, Hu, S, Shen, V, Bara, I, Schulze, K, Montesion, M, Skoulidis, F, Negrão, M

September 2019

Abstract

World Conference on Lung Cancer

Real-world outcomes of advanced NSCLC patients with common and uncommon/complex EGFR mutation profiles →

Riely, GJ, Lovly, CM, Messina, CGM, Bienert, S, Alexander, K, Pao, W, Magee, K, Baxi, SS, Doebele, RC

September 2019

Abstract

World Conference on Lung Cancer

Flatiron-authored

Real-world survival of relapsed compared to de-novo stage IV diagnosis of advanced non-small cell lung cancer →

Kerrigan, KC, Halland, B, Adamson, BJS, Patel, SB, Akerley, WL

September 2019

Abstract

World Conference on Lung Cancer

Flatiron-authored

Real-world characterization of advanced non-small cell lung cancer in never smokers →

Kerrigan, KC, Halland, B, Adamson, BJS, Patel, SB, Akerley, WL

September 2019

Abstract

World Conference on Lung Cancer

Flatiron-authored

Retrospective analysis of real-world clinico-genomic data for clinical impact of genomic profiling of CTDNA in NSCLC →

Madison, R, Schrock, AB, Gregg, JP, Carson, KR, Castellanos, EH, Singal, G, Miller, VA, Ali, SM, Alexander, BM, Chung, JH

September 2019

Abstract

World Conference on Lung Cancer

Flatiron-authored

Comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients →

Doebele, RC, Perez, L, Trinh, H, Martinec, M, Martina, R, Riehl, T, Krebs, MG, Meropol, NJ, Wong, WB, Crane, G

September 2019

Abstract

World Conference on Lung Cancer

Flatiron-authored

Treatment pattern and real-world effectiveness on non-small cell lung cancer patients harboring major single and double EGFR mutations →

So, WV, Yang, X, Leddin, M, Chen, L, Nagel, YA

August 2019

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Deep learning-based propensity score computation: Cohort study in second line treated advanced non-small cell lung cancer (aNSCLC) patients →

Weberpals, J, Becker, T, Schmich, F, Rüttinger, D, Theis, FJ, Bauer-Mehren, A

August 2019

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Validation of an algorithm to predict treatment discontinuation status in electronic health records →

Davies, J, Sanglier, T, Shim, J, Hibbert, A, Taylor, MD, Carson, KR

August 2019

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Flatiron-authored

Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non–small-cell lung cancer data set →

Griffith SD, Miksad RA, Calkins G, You P, Lipitz NG, Bourla AB, Williams E, George DJ, Schrag D, Khozin S, Capra WB, Taylor MD, Abernethy AP

August 2019

Manuscript

JCO Clinical Cancer Informatics

Flatiron-authored

Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer →

Khozin S, Miksad RA, Adami J, Boyd M, Brown NR, Gossai A, Kaganman I, Kuk D, Rockland JM, Pazdur R, Torres AZ, Zhi J, Abernethy AP

August 2019

Manuscript

Cancer

Flatiron-authored

Using Electronic Health Records to Derive Control Arms for Early Phase Single‐Arm Lung Cancer Trials: Proof‐of‐Concept in Randomized Controlled Trials →

Carrigan G, Whipple S, Capra WB, Taylor MD, Brown JS, Lu M, Arnieri B, Copping R, Rothman KJ

July 2019

Manuscript

Clinical Pharmacology and Therapeutics

An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non-small-cell lung cancer →

Stewart M, Norden AD, Dreyer N, Henk HJ, Abernethy AP, Chrischilles E, Kushi L, Mansfield AS, Khozin S, Sharon E, Arunajadai S, Carnahan R, Christian JB, Miksad RA, Sakoda LC, Torres AZ, Valice E, Allen J

July 2019

Manuscript

JCO Clinical Cancer Informatics

Flatiron-authored

Cost effectiveness of multigene panel sequencing for patients with advanced non–small-cell lung cancer →

Steuten, L, Goulart, B, Meropol, NJ, Pritchard, D, Ramsey, SD

June 2019

Manuscript

JCO Clinical Cancer Informatics

Flatiron-authored

First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: Real-world analysis of time on treatment →

Velcheti V, Chandwani S, Chen X, Pietanza MC, Burke T

June 2019

Manuscript

Immunotherapy

Affordable Care Act Medicaid expansion impact on racial disparities in time to cancer treatment →

Adamson B, Cohen AB, Estevez M, Magee K, Williams E, Gross CP, Meropol NJ, Davidoff AJ

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Organ dysfunction and clinical outcomes in patients treated with immune checkpoint inhibitors →

Liu Q, Sharon E, Zineh I, Xie D, Baxi SS, Liu C, Zhi J, Torres AZ, Gossai A, Sridhara R, Booth B, Blumenthal GM, Huang S-M, Khozin S

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Tumor mutational burden and PD-L1 expression as predictors of response to immunotherapy in NSCLC →

Castellanos E, Snider J, Ali SM, Backenroth D, Albacker LA, Murugesan K, Li G, Frampton GM, Alexander BM, Carson KR

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Time-to-treatment discontinuation and real-world progression-free survival as endpoints for comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive NSCLC patients →

Doebele RC, Perez L, Trinh H, Martinec M, Martina R, Riehl T, Krebs M, Meropol NJ, Wong WB, Crane G

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC →

Riely GJ, Lovly CM, Messina C, Bienert S, Alexander K, Pao W, Baxi S, Doebele RC

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Genomic characterization of lung tumors and metastatic sites in advanced NSCLC →

Willard MD, Smyth EN, Tiu RV, Beyrer J, Zhu YE, Bowman L, Sheffield KM, Han Y, Brastianos P

June 2019

Abstract

ASCO Annual Meeting

Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer, bladder cancer, and melanoma: An electronic health records study →

Sadetsky N, Chuo C-Y, Davidoff AJ

June 2019

Abstract

ASCO Annual Meeting

Real-world clinical burden of aggressive disease in advanced/metastatic non small cell lung cancer →

Batus M, Stefaniak VJ, Molife C, Clarke JM, Winfree KB, Mitchell L, Cui ZL, Bonom PD

June 2019

Abstract

ASCO Annual Meeting

Association of patient characteristics with real-world ROS1 NSCLC testing patterns among community practices in the United States →

Wong WB, Wu N, Gupta R, Mansfield AS

June 2019

Abstract

ASCO Annual Meeting

Is a delay in ALK inhibitor initiation associated with poorer survival? A retrospective analysis based on real-world data →

Sheinson D, Wong WB, Wu N, Mansfield AS

June 2019

Abstract

ASCO Annual Meeting

Biomarker testing, treatment and survival outcomes in Medicaid compared to commercially insured patients with advanced NSCLC →

Yim YM, Wu N, Wong WB

June 2019

Abstract

ASCO Annual Meeting

Value of precision medicine in advanced NSCLC: Real-world outcomes associated with the use of companion diagnostics →

John A, Shah R, Wong WB, Schneider C, Gari HH, Johnson M

June 2019

Abstract

ASCO Annual Meeting

Impact of antibiotics on overall survival in patients with advanced non-small-cell lung cancer and melanoma treated with first-line immune checkpoint inhibition →

Bagley SJ, Dhopeshwarkar N, Narayan V, Meropol NJ, Mamtani R, Boursi B.

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Real-world clinical outcomes for advanced/metastatic non-small cell lung cancer patients treated with second line ramucirumab plus docetaxel post frontline platinum based chemotherapy plus immune checkpoint inhibitors →

Clarke JM, Mathur R, Molife C, Batus M, Stefaniak VJ, Winfree KB, Baxi S, Cui ZL, Lenis D, Bonomi PD

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Real-world tumor response to ramucirumab plus docetaxel post platinum-based and immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients →

Clarke JM, Mathur R, Molife C, Batus M, Stefaniak VJ, Winfree KB, Baxi S, Cui ZL, Lenis D, Bonomi PD

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Identification and use of treatment options in patients with advanced non-small cell lung cancer after comprehensive genomic profiling: A real-world study →

Mascaux C, Bubendorf L, Barlesi F, Clendening JW, Zhang Q, Mace K, Gondos A, Foser S, Wang L, Paz-Ares LG

June 2019

Abstract

ASCO Annual Meeting

Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer →

Leapman M, Presley CJ, Zhu W, Soulos PR, Adelson KB, Boffa DJ, Gross CP

June 2019

Abstract

ASCO Annual Meeting

Clinical characteristics, treatment patterns, and overall survival in advanced NSCLC patients with and without brain metastases →

Smyth EN, Tiu RV, Willard MD, Beyrer J, Zhu YE, Bowman L, Sheffield KM, Han Y, Brastianos P

June 2019

Abstract

ASCO Annual Meeting

Validation of broad panel clinical sequencing-based genomic risk stratification in patients with advanced lung adenocarcinomas →

Whipple S, Martin A, Martinec M, Arbour KC, Seshan VE, Riely GJ, Crane G, Shen R

June 2019

Abstract

ASCO Annual Meeting

Comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients →

Doebele, RC, Perez, L, Trinh, H, Martinec, M, Martina, R, Riehl, T, Krebs, MG, Meropol, NJ, Wong, WB, Crane, G

May 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Generating real-world tumor burden endpoints from electronic health record data: Comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer →

Griffith S, Tucker M, Bowser B, Calkins G, Chang C-H, Guardino E, Khozin S, Kraut J, You P, Schrag D, Miksad RA

May 2019

Manuscript

Advances in Therapy

Flatiron-authored

Comparative effectiveness of carboplatin/pemetrexed with versus without bevacizumab for advanced nonsquamous non-small cell lung cancer →

Bagley SJ, Talento S, Mitra N, Meropol NJ, Cohen RB, Laner CJ, Vachani A

May 2019

Manuscript

JNCCN

Flatiron-authored

The Impact of Delaying ALK Inhibitor Therapy on Outcomes: A Prescription Time Matching Method →

Sheinson D, Wu N, Wong W

May 2019

Abstract

ISPOR Annual Meeting

Real World Effectiveness of Nivolumab in Asian Patients in the United States Flatiron Health Database →

Allan V, Mungul A, Diaz J, Luo T, Harish A, Ramagopalan S, Chang J

May 2019

Abstract

ISPOR Annual Meeting

Machine Learning Model for Cancer Biomarker Identification in Electronic Health Records →

Ambwani G, Cohen A, Estévez M, Singh N, Adamson B, Nussbaum N, Birnbaum B

May 2019

Abstract

ISPOR Annual Meeting

Flatiron-authored

Real-world clinical impact of immune checkpoint inhibitors in patients with advanced/metastatic non-small cell lung cancer after platinum chemotherapy →

Schwartzberg L, Korytowsky B, Penrod JR, Zhang Y, Le TK, Batenchuk C, Krug L

April 2019

Manuscript

Clinical Lung Cancer

Real-world immuno-oncology therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive non-small cell lung cancer in the United States →

Pan X, Lin MM, Yin Y, Hou P, Baumann P, Jahanzeb M

April 2019

Abstract

European Lung Cancer Conference

Treatment characteristics of patients with locally advanced or metastatic non-small cell lung cancer receiving atezolizumab monotherapy in US clinical practice →

Frueh M, Rahma OE, Pachynski RK, Mazieres J, Goldschmidt, Jr J, Ton TGN, Mhatre SK, Chuo C-Y, Martinalbo J, Davies J, Juergens R.

April 2019

Abstract

European Lung Cancer Conference

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database →

Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert E, Bourque D, O’Connell C, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Alpha-Cobb G, Guria A, He J, Frank S, Nunnally A, Bailey M, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller VA.

April 2019

Manuscript

JAMA

Flatiron-authored

Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC) →

Velcheti V, Chandwani S, Chen X, Pietanza MC, Burke T.

April 2019

Abstract

AACR Annual Meeting

An evaluation of the impact of missing deaths on overall survival analyses of advanced non–small cell lung cancer patients conducted in an electronic health records database →

Carrigan, G, Whipple, S, Taylor, MD, Torres, AZ, Gossai, A, Arnieri, B, Tucker, M, Hofmeister, PP, Lambert, P, Griffith, SD, Capra, WB

March 2019

Manuscript

Pharmacoepidemiology & Drug Safety

Flatiron-authored

Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice →

Molife C, Hess LM, Cui ZL, Li XI, Beyrer J, Mahoui M, Oton AB

February 2019

Manuscript

Future Oncology

Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer →

Riaz, F, Presley, CJ, Chiang, AC, Longtine, JA, Soulos, PR, Adelson, KB, Herbst, RS, Nussbaum, NC, Sorg, RA, Abernethy, AP, Agarwala, V, Gross, CP

February 2019

Manuscript

Journal of Geriatric Oncology

Flatiron-authored

Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USA →

Li Y, Appius A, Pattipaka T, Feyereislova A, Cassidy A, Ganti AK

January 2019

Manuscript

PLoS One

Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval →

Khozin S, Carson KR, Zhi J, Tucker M, Lee SE, Light DE, Curtis MD, Bralic M, Kaganman I, Gossai A, Hofmeister PP, Torres AZ, Miksad RA, Blumenthal GM, Pazdur R, Abernethy AP

December 2018

Manuscript

The Oncologist

Flatiron-authored

First-line pembrolizumab monotherapy in metastatic PD-L1 positive non-small cell lung cancer: A real-world analysis of time on treatment in US community oncology practices →

V Velcheti, S Chandwani, X Chen M, C Pietanza, T Burke

December 2018

Abstract

ESMO Immuno-Oncology Congress

Treatment Patterns, Duration and Outcomes of Pemetrexed Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting →

Winfree KB, Torres AZ, Zhu Y, Muehlenbein C, Aggarwal H, Woods S, Abernethy AP

December 2018

Manuscript

Current Medical Research and Opinion

Flatiron-authored

Temporally integrated framework for treatment intervals (TIFTI): A framework for extracting drug intervals from longitudinal clinic notes →

Agrawal, M, Adams, G, Nussbaum, NC, Birnbaum, B

December 2018

Abstract

Machine Learning for Health (ML4H) Workshop

Flatiron-authored

Real-World Anaplastic Lymphoma Kinase (ALK) Rearrangement Testing Patterns, Treatment Sequences, and Survival of ALK Inhibitor-Treated Patients →

Davies J, Martinec M, Coudert M, Delmar P, Crane G

November 2018

Manuscript

Current Medical Research and Opinion

Real-World Progression-Free Survival of Patients on Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) for ALK+ Non-Small Cell Lung Cancer (NSCLC) →

Jahanzeb M

October 2018

Abstract

ESMO Annual Congress

Identification of Genomic Markers of Sensitivity and Resistance to Checkpoint Inhibitors in Non-Small Cell Lung Cancer in a Real World Clinico-Genomic Database →

Murugesan K

October 2018

Abstract

ESMO Annual Congress

ALK Testing Trends and Patterns Among Community Practices in the United States →

Illei P, Wong W, Wu N, Chu L, Gupta R, Schulze K, Gubens M

October 2018

Manuscript

JCO Precision Oncology

Sequencing of Ramucirumab+Docetaxel Postimmune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer →

Clarke JM, Stefaniak VJ, Batus M, Winfree KB, Molife C, Cui Z, Han Y, Tawney MK, Bonomi PD

September 2018

Abstract

World Conference on Lung Cancer

Prognosis of Non-Driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC) →

Chalmers AW, Haaland B, Patel SB, Moynahan K, Cannon L, Akerley W

September 2018

Abstract

World Conference on Lung Cancer

Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients →

Batus M, Molife C, Clarke JM, Stefaniak VJ, Winfree KB, Cui Z, Han Y, Tawney MK, Bonomi PD

September 2018

Abstract

World Conference on Lung Cancer

Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients →

Barlesi F, Paz-Ares L, Page D, Shewade A, Lambert P, Mughal T, Gay L, Khorshid M, Arnieri B, Capra W, Foser S, Mascaux C, Bubendorf L, Wang L

September 2018

Abstract

World Conference on Lung Cancer

Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR TKIs →

Chiang A, Fernandes A, Pavilack M, Wu J, Laliberté F, Duh MS, Chehab N, Subramanian J

September 2018

Abstract

World Conference on Lung Cancer

An Observational Study of Concomitant Immunotherapies and Denosumab in Patients with Advanced Melanoma or Lung Cancer →

Liede A, Hernandez RK, Wade S, Bo R, Nussbaum N, Ahern E, Dougall WC, Smyth MJ

September 2018

Manuscript

OncoImmunology

Flatiron-authored

Using similarity metrics on real-world data to recommend the next treatment →

Haas, K, Mahoui, M, Gupta, S, Morton, S

August 2018

Abstract

ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics

The Impact of Missing Deaths on Survival Analyses Conducted in an Oncology EHR Database →

Carrigan G, Whipple S, Taylor M, Torres AZ, Gossai A, Arnieri B, Tucker M, Hofmeister PP, Lambert P, Griffith S, Capra W

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Flatiron-authored

Proof-of-Concept for using External Control Arms Derived from Electronic Health Records (EHR) to Replace Control Arms from Randomized Controlled Trials (RCT) →

Carrigan G, Whipple S, Capra W, Taylor M, Lu M, Arnieri B, Brown JS, Abernethy AP, Copping R, Rothman KJ

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Flatiron-authored

Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Setting →

Presley C, Tang D, Soulos P, Chiang A, Longtine J, Adelson K, Herbst R, Zhu W, Nussbaum N, Sorg R, Agarwala V, Abernethy AP, Gross C

August 2018

Manuscript

JAMA

Flatiron-authored

Disparities in the use of programmed death 1 immune checkpoint inhibitors →

O’Connor, JM, Seidl-Rathkopf, K, Torres, AZ, You, P, Carson, KR, Ross, JS, Gross, CP

July 2018

Manuscript

The Oncologist

Flatiron-authored

Comparative Effectiveness from a Single-Arm Trial and Real-World Data: Alectinib versus Ceritinib →

Davies J, Martinec M, Delmar P, Coudert M, Bordogna W, Golding S, Reynaldo M, Crane G

June 2018

Manuscript

Future Medicine

Development and Validation of a High-Quality Composite Real-World Mortality Endpoint →

Curtis MD, Griffith S, Tucker M, Taylor M, Capra W, Carrigan G, Holzman B, Torres AZ, You P, Arnieri B, Abernethy AP

June 2018

Abstract

Academy Health Annual Research Meeting

Flatiron-authored

Cost-Effectiveness of Multi-Gene Panel Sequencing (MGPS) for Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients →

Steuten LM, Goulart B, Meropol N, Pritchard D, Ramsey SD

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Diffusion of Innovation in Oncology: A Case Study of Immuno-Oncology (IO) Adoption for Advanced Non-Small Lung Cancer (aNSCLC) Patients Across Practices in the US →

Bennette CS, Torres AZ, Tucker M, Khozin S, Abernethy AP, Brown NR, Meropol N

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Application of a Real World Endpoint to Identify and Characterize Genetic Profiles of Patients (pts) with Poor Prognosis in Advanced Non-Small-Cell Lung Cancer (aNSCLC) →

Crane G, Trunzer K, Whipple S, Cuenco K, Tolson J, Kathuria B, Das-Gupta A

June 2018

Abstract

ASCO Annual Meeting

Real-world Data (RWD) on Tumor Response (rwTR) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients Receiving Cancer Immunotherapy and Targeted Therapies →

Lu M, Sadetsky N, Lambert P, Whipple S, Taylor M, Riehl T, Riely GJ

June 2018

Abstract

ASCO Annual Meeting

Risk Stratification Using Patient-Reported Outcomes (PROs) in Patients (pts) with Advanced Cancer →

Patel SB, Haaland B, Ose D, Haydell T, Martineau J, Dunson W, Chalmers AW, Cannon L, Kissell B, Meropol N, Akerley W

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Association of Baseline Body Mass Index (BMI) with Overall Survival (OS) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (mNSCLC) Treated with Nivolumab (N) and Pembrolizumab (P) →

Zhi J, Khozin S, Kuk D, Torres AZ, Sorg R, Lee S, Miksad RA, Pazdur R, Abernethy AP

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Comparative Effectiveness of Carboplatin-Pemetrexed (Carbo-Pem) with vs. without Bevacizumab (Bev) in Patients with Advanced Non-Squamous (Sq) Non-Small Cell Lung Cancer (NSCLC) →

Bagley S, Mitra N, Meropol N, Holzman B, Cohen R, Langer C, Vachani A

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

An Observational Study of Concomitant Immunotherapies and Denosumab in Patients with Advanced Melanoma or Lung Cancer →

Liede A, Hernandez RK, Wade S, Bo R, Ahern E, Dougall WC, Smyth MJ

June 2018

Abstract

ASCO Annual Meeting

Real-World Characteristics, Treatment Patterns and Outcomes of RET+ NSCLC Compared to Other Rare Driver Mutations →

Wong W, Wu N, Gupta R

June 2018

Abstract

ASCO Annual Meeting

Sequencing of Ramucirumab (ram) and Immune Checkpoint Inhibitors (ICIs) in Platinum (Pt)-Treated Real-World Patients (pts) with Advanced Non-Small Cell Lung Cancer (aNSCLC) →

Clarke JM, Molife C, Miksad RA, Batus M, Winfree KB, Gossai A, Stefaniak VJ, Foster R, Cui Z, Torres AZ, Feuchtbaum D, Tawney MK, Bonomi PD

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Identifying the Prognostic Significance of Genomic Alterations in a Real-World, EHR-Derived Clinico-Genomic Database (CGDB) →

Agarwala V, Backenroth D, Singal G, O'Connell C, Li G, Alpha-Cobb G, Kaushik G, Carson K, Miller V, Abernethy AP

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Prevalence of Microsatellite Instability and Association with Pembrolizumab (P) Usage in a Real-World Clinico-Genomic Database →

O'Connell C, Backenroth D, Singal G, Agarwala V, Li G, Kaushik G, Alpha-Cobb G, Kao CK, Miller V, Abernethy AP, Carson K

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Ramucirumab (ram), Immune Checkpoint Inhibitors (ICIs), and Single-Agent Chemotherapy (chemo) Usage in Real-World Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients (pts) after Rapid Disease Progression (RDP) on Platinum (Pt) →

Batus M, Molife C, Miksad RA, Clarke JM, Stefaniak VJ, Foster R, Winfree KB, Gossai A, Cui Z, Torres AZ, Feuchtbaum D, Tawney MK, Bonomi PD

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Comparison of Structured Versus Abstracted Comorbidities Using Oncology EHR Data from Cancer Patients in the Flatiron Health Network →

Parrinello CM, Seidl-Rathkopf K, Bennette CS, Bourla A, Nussbaum N, Carson K, Abernethy AP

May 2018

Abstract

ISPOR Annual Meeting

Flatiron-authored

Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials →

O’Connor J, Fessele K, Steiner J, Seidl-Rathkopf K, Carson K, Nussbaum N, Yin E, Adelson K, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

May 2018

Manuscript

JAMA Oncology

Flatiron-authored

Identification of Resistance Mechanisms to EGFR Treatment in the Real World Using a Clinicogenomic Database →

Singal G, Agarwal A, Kaushik G, O'Connell C, Alpha-Cobb G, Caron T, Bourque D, Guria A, Frank S, Frampton G, Carson K, Abernethy AP, Miller V

April 2018

Abstract

American Association for Cancer Research Annual Meeting

Flatiron-authored

Use of Cancer Immunotherapies in the Real-World in the Setting of Microsatellite Instability →

Agarwala V, Gossai A, Singal G, O'Connell C, Li G, Kao K, Bourque D, Feuchtbaum D, Nunnally A, Frampton G, Ali S, Abernethy AP, Kramarz S, Trabucco SE

January 2018

Abstract

ASCO-SITC Clinical Immuno-Oncology Symposium

Flatiron-authored

Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval →

Khozin S, Abernethy AP, Nussbaum N, Zhi J, Curtis MD, Tucker M, Lee S, Light D, Gossai A, Sorg R, Torres AZ, Patel P, Blumenthal G, Pazdur R

January 2018

Manuscript

The Oncologist

Flatiron-authored

Distribution of PD-L1 Tumor Expression By Assay Type in Patients with Metastatic NSCLC (mNSCLC) →

Velcheti A, Cao X, Liu F, Patwardhan P

October 2017

Abstract

World Conference on Lung Cancer

Utilization and Timing of Foundation Medicine (FMI) Testing in U.S. Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients →

Wang L, Page D, Shewade A, Lambert P, Arnieri B, Capra W, Khorshid M, Mughal T, Gay L, Foser S

October 2017

Abstract

World Conference on Lung Cancer

Real-World Patient Characteristics, Testing and Treatment Patterns of ALK+ NSCLC →

Gubens M, Wong W, Wu N, Chu L, Schulze K, Illei P

October 2017

Abstract

World Conference on Lung Cancer

ALK Testing Trends and Patterns Among Community Practices in the United States →

Illei P, Wong W, Wu N, Chu L, Schulze K, Gubens M

October 2017

Abstract

World Conference on Lung Cancer

Real-World Management of Patients with EGFR Mutation-Positive NSCLC in the US →

Li Y, Appius A, Pattipaka T, Feyereislova A, Cassidy A, Ganti A

October 2017

Abstract

World Conference on Lung Cancer

Biomarker Testing Trends and Treatment Patterns in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients in the United States →

Chu L, Corvino F, Yi J, Zikovic M, Wong W

October 2017

Abstract

World Conference on Lung Cancer

Immune Checkpoint Inhibitor (ICPI) Efficacy and Resistance Detected by Comprehensive Genomic Profiling (CGP) in Non-Small Cell Lung Cancer (NSCLC) →

Ross J, Goldberg M, Albacker L, Gay L, Agarwala V, Elvin J, Vergillo J, Ramkissoon S, Severson E, Daniel S, Ali S, Schrock A, Frampton G, Fabrizio D, Miller V, Singal G, Abernethy AP, Stephens P

September 2017

Abstract

ESMO Annual Congress

Flatiron-authored

Analyzing Biomarkers of Cancer Immunotherapy (CIT) Response Using a Real-World Clinico-Genomic Database →

Singal G, Miller P, Agarwala V, Li G, Gossai A, Albacker L, Goldberg M, He J, Frank S, Bourque D, Ivanov V, Fabrizio D, Caron T, Parker A, Guria A, Miller V, Elvin J, Ross J, Abernethy AP, Stephens P

September 2017

Abstract

ESMO Annual Congress

Flatiron-authored

Real-World First-Line Treatment and Overall Survival in Non-Small Cell Lung Cancer Without Known EGFR Mutations or ALK Rearrangements in US Community Oncology Setting →

Abernethy AP, Arunachalam A, Burke T, McKay C, Cao X, Sorg R, Carbone D

June 2017

Manuscript

PLoS One

Flatiron-authored

Adoption of Immunotherapy into Real World Practice: Insights from the Use of Checkpoint Inhibitors →

O’Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres AZ, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Racial Disparities in the Use of Programmed Death-1 Checkpoint Inhibitors →

O’Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres AZ, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Disparities in Next Generation Sequencing in a Population-Based Community Cohort of Patients with Advanced Non-Small Cell Lung Cancer →

Presley C, Chiang A, Longtine J, Soulos P, Adelson K, Herbst R, Nussbaum N, Sorg R, Abernethy AP

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Development and Validation of a Real-World Clinico-Genomic Database →

Singal G, Miller P, Agarwala V, He J, Gossai A, Frank S, Bourque D, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Parker A, Guria A, Frampton G, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller V

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored